GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » E10

Amgen (BUE:AMGN) E10 : ARS477.77 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Amgen E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Amgen's adjusted earnings per share data for the three months ended in Dec. 2024 was ARS5,858.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS477.77 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Amgen's average E10 Growth Rate was 1.70% per year. During the past 3 years, the average E10 Growth Rate was 6.60% per year. During the past 5 years, the average E10 Growth Rate was 9.10% per year. During the past 10 years, the average E10 Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Amgen was 25.30% per year. The lowest was 6.20% per year. And the median was 16.40% per year.

As of today (2025-03-24), Amgen's current stock price is ARS13450.00. Amgen's E10 for the quarter that ended in Dec. 2024 was ARS477.77. Amgen's Shiller PE Ratio of today is 28.15.

During the past 13 years, the highest Shiller PE Ratio of Amgen was 35.25. The lowest was 18.58. And the median was 26.26.


Amgen E10 Historical Data

The historical data trend for Amgen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen E10 Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.97 202.64 376.31 1,155.89 477.77

Amgen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,155.89 433.92 535.35 501.28 477.77

Competitive Comparison of Amgen's E10

For the Drug Manufacturers - General subindustry, Amgen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Shiller PE Ratio falls into.



Amgen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=5858/133.1571*133.1571
=5,858.000

Current CPI (Dec. 2024) = 133.1571.

Amgen Quarterly Data

per share eps CPI Adj_EPS
201503 93.048 99.621 124.371
201506 97.680 100.684 129.184
201509 114.708 100.392 152.146
201512 153.375 99.792 204.655
201603 182.550 100.470 241.940
201606 172.650 101.688 226.079
201609 199.884 101.861 261.297
201612 205.290 101.863 268.359
201703 215.067 102.862 278.408
201706 239.900 103.349 309.092
201709 241.824 104.136 309.218
201712 -562.348 104.011 -719.929
201803 327.421 105.290 414.081
201806 433.956 106.317 543.511
201809 526.226 106.507 657.900
201812 567.460 105.998 712.857
201903 621.531 107.251 771.663
201906 797.520 108.070 982.659
201909 914.390 108.329 1,123.956
201912 851.774 108.420 1,046.114
202003 952.764 108.902 1,164.973
202006 1,044.015 108.767 1,278.123
202009 1,273.216 109.815 1,543.850
202012 1,123.044 109.897 1,360.743
202103 1,274.632 111.754 1,518.744
202106 383.657 114.631 445.660
202109 1,618.259 115.734 1,861.874
202112 1,696.632 117.630 1,920.595
202203 1,438.786 121.301 1,579.415
202206 1,474.043 125.017 1,570.023
202209 2,765.105 125.227 2,940.219
202212 2,514.750 125.222 2,674.110
202303 5,215.320 127.348 5,453.230
202306 3,084.000 128.729 3,190.093
202309 5,634.195 129.860 5,777.267
202312 2,563.100 129.419 2,637.124
202403 -884.625 131.776 -893.895
202406 6,178.950 132.554 6,207.073
202409 24,808.049 133.029 24,831.957
202412 5,858.000 133.157 5,858.000

Add all the adjusted EPS together and divide 10 will get our e10.


Amgen  (BUE:AMGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Amgen's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=13450.00/477.77
=28.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Amgen was 35.25. The lowest was 18.58. And the median was 26.26.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Amgen E10 Related Terms

Thank you for viewing the detailed overview of Amgen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.